In part 3 of this Exclusive Interview about the new diabetes classification, facilitating the individual use of “evidence-based practice” to individually assess the situation of a specific patient, instead of allowing media supposition about a drug class — such as SGLT-2s — to dictate diabetes treatment.
A transcript of this interview is available. Click here to read.
Stanley Schwartz, MD, Emeritus Associate Professor of Medicine at the University of Pennsylvania, has been awarded the honor of being a TOP DOC by Philadelphia Magazine many times over the years, including 2009, 2010 and 2011 for the treatment of diabetes and metabolic syndrome. For over 30 years, Dr. Schwartz was an Associate Professor at the University of Pennsylvania, most recently directing the Diabetes Program at the Philadelphia Heart Institute. Dr. Schwartz actively lectures nationally as well as internationally about diabetes and its treatment. He has authored numerous articles in peer-reviewed scientific journals and has been a lead or co-investigator for many clinical trials.